Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Parker, Chris; Nilsson, Sten; Heinrich, Daniel; Inge Helle, Svein; M. O’Sullivan, Joe; D. Fosså, Sophie; Chodacki, Aleš; Wiechno, Paweł; Logue, John; Seke, M.; Widmark, Anders; Clement Johannessen, Dag; Hoskin, Peter; Bottomley, David; D. James, Nicholas; Solberg, A.; Syndikus, Isabel; Kliment, J.; Wedel, Saskia; Boehmer, S.; F. Dall’Oglio, Marcos; Franzén, Lars; E. Coleman, Robert; J. Vogelzang, Nicholas; Gillies O'Bryan-Tear, C.; Staudacher, K.; Garcia‐Vargas, J.; Shan, Minghua; S. Bruland, Øyvind; Sartor, Oliver

doi:10.1056/nejmoa1213755

Public

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Published in New England Journal of Medicine • Jul 17, 2013

Authors:

Chris Parker

Sten Nilsson

Daniel Heinrich

Abstract

BACKGROUND: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone ...

Subject

Medicine

Hazard ratio

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!